Temozolomide for recurrent high-grade glioma

Seminars in Oncology

Volumn 28, Issue 4 SUPPL. 13, 2001, Pages 3-12

  Macdonald, David R ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PROCARBAZINE; TEMOZOLOMIDE;

CANCER RECURRENCE; CANCER SURVIVAL; CANCER THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; GLIOBLASTOMA; HUMAN; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; REVIEW; TUMOR GROWTH;

EID: 0034820946     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2001.26648     Document Type: Review

References (15)

1. Cancer statistics, 2000
2. Practical guidelines for the treatment of malignant gliomas
3. Neoplasms of the central nervous system
4. Temozolomide
5. A phase II study of temozolomide versus procarbazine in patients with glioblastoma multiforme at first relapse
6. Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse
7. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse
8. Subjective measures of well being
9. A validation study of the domains of the core EORTC quality of life questionnaire
10. The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires
11. Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme
12. Health-related quality of life in patients with anaplastic astrocytoma during treatment with temozolomide